Table 4. 5-year cumulative incidence of each recurrence pattern for GC patients with and without CD44 isoform expression at the invasive tumour front.

	CD44s expression at invasive tumour front			CD44v6 expression at invasive tumour front			CD44v9 expression at invasive tumour front
	Positive	Negative		Positive	Negative		Positive	Negative
Recurrence pattern	% (95% CI)	% (95% CI)	P-value	% (95% CI)	% (95% CI)	P-value	% (95% CI)	% (95% CI)	P-value
Peritoneal recurrence rate	43.4% (14.1–70.0%)	5.8% (2.4–11.5%)	<0.001a	13.8% (7.0–22.8%)	2.4% (0.2–11.2%)	0.007a	21.2% (10.3–34.6%)	2.9% (0.5–9.0%)	0.041a
Lymphatic recurrence rate	51.3% (12.1–80.9%)	4.3% (1.4–10.0%)	<0.001a	11.0% (4.8–20.1%)	2.8% (0.2–12.8%)	0.108	14.6% (5.2–28.6%)	4.6% (1.2–11.7%)	0.062
Haematogenous recurrence rate	29.4% (5.4–59.7%)	6.2% (2.5–12.2%)	0.008a	8.7% (3.5–16.9%)	7.3% (1.8–18.1%)	0.719	12.9% (4.6–25.6%)	5.7% (1.8–13.0%)	0.156

Abbreviations: CD44s=CD44 standard isoform; CD44v6=CD44 variant isoform 6; CD44v9=CD44 variant isoform 9; CI=confidence interval; GC=gastric cancer.

^aStatistically significant.